Kormo Medicine has completed tens of millions of RMB in Series B1 financing.

Recently, Kommer Pharmaceuticals announced the completion of tens of millions of RMB in Series B1 financing. This round of financing was jointly invested by Lianyungang Industrial Investment Fund and existing shareholder Bangsheng Capital. The funds raised will be used for the development of innovative business and research and development platform of Kommer Pharmaceuticals.